Risedronate Sodium Tablet, Delayed Release
Product Images NDC 59762-0407

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 59762-0407). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Following Chemical Structure Of Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Risedronate Sodium Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Risedronate Sodium 01)

FDA Label Image

Figure 1 (Risedronate Sodium 02)

The figure shows the cumulative incidence of nonvertebral osteoporosis-related fractures over 3 years for patients taking placebo and ACTONEL 5mg. The fractures are categorized by location, including the wrist, humerus, hip, pelvis, leg, and clavicle. The text "9% of Patients" is not related to the figure and may refer to a statistic in the accompanying text that is not included here.*

FDA Label Image

Principal Display Panelndc 59762-0407-4risedronate Sodiumdelayed-release Tablets35 mg4 Tabletsonce-a-weekrx Only (Risedronate Sodium 03)

FDA Label Image

Risedronate Sodium 04

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.